美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Neuroscience and Healthcare ETF

36.20

0.0000

成交量：87

成交額：3,165.58

市值：723.97萬

市盈率：- -

高：36.20

開：36.20

低：36.20

收：36.20

52周最高：43.01

52周最低：25.42

股本：20.00萬

流通股本：20.00萬

量比：0.50

換手率：0.04%

股息：0.32

股息率：0.88%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

9月10日起實施浙江出台18條舉措，推進腦機接口領域發展

美國研究綜述-愛彼迎、Five Below、Silgan Holdings

美銀證券：中國CXO行業受惠生物科技融資強勁上調藥明康德等目標價

尹弘在贛江新區調研：全力以赴搶佔產業新賽道打造新的增長點奮發有為創造一流業績展現新區發展水平

尹弘在贛江新區調研：全力以赴搶佔產業新賽道打造新的增長點奮發有為創造一流業績展現新區發展水平

韓國政府：計劃在2035年前實現腦機接口產品的商業化。

浙江省：到2027年腦機接口未來產業營收超過50億元

腦機接口板塊走高，創新醫療漲停

浙江：鼓勵腦機接口企業自主合理定價開通醫用耗材掛網「綠色通道」

浙江：強化腦機接口企業全生命周期金融支持推動腦機接口企業選擇合適上市方式

人保財險簽發全國首單腦機接口手術意外險

人保財險簽發全國首單腦機接口手術意外險

賓利把神經科學塞進車裏！首款純電Torcal內飾公開：座艙根據情緒變氛圍

「蒸餾」你的大腦，腦機這門生意竟然價值上億

更正-Scholar Rock將諾和諾德的生產設施從肌肉無力藥物的上市申請中剔除

Scholar Rock 因FDA質控警告，將諾和諾德工廠從藥物申請中剔除

Scholar Rock Holding Corporation 已全面就緒，只待FDA批准即刻啓動Apitegromab美國上市

Scholar Rock宣佈FDA受理Apitegromab治療脊髓性肌萎縮症（SMA）的生物製品許可申請（BLA），並推進第二家灌裝-封裝工廠建設；預計2026年9月30日前作出審批決定

Scholar Rock Holding Corp 與歐洲藥品管理局溝通，計劃將第二家灌裝-封裝設施納入Apitegromab上市申請

「蒸餾」你的大腦，腦機這門生意竟然價值上億

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IBRN/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":36.1985,"timestamp":1789567712610,"preClose":36.1985,"halted":0,"volume":87,"delay":0,"changeRate":0,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-16 10:14:21 EDT","open":36.1985,"high":36.1985,"low":36.1985,"amount":3165.58026,"amplitude":0,"askPrice":36.24,"askSize":400,"bidPrice":35.99,"bidSize":400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":36.1985,"sharesOutstanding":150000,"nav":37.284354,"aum":7456870.8,"dividendRate":0.008801,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":36.35,"preClose":36.1985,"latestTime":"17:17 EDT","volume":7,"amount":253.794,"timestamp":1789507022693,"change":0.1515,"changeRate":0.004185,"amplitude":0},"volumeRatio":0.496903,"impliedVol":0.1976,"impliedVolPercentile":0.9124},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.496903,"shares":200000,"dividePrice":0.3186,"high":36.1985,"amplitude":0,"preClose":36.1985,"low":36.1985,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":36.1985,"eps":0,"divideRate":0.008801,"volume":87,"delay":0,"ttmEps":0,"open":36.1985,"prevYearClose":32.3193,"prevWeekClose":37.4262,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":37.9959,"twentyDayClose":39.7665,"sixtyDayClose":36.6691},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659113553","title":"9月10日起實施 浙江出台18條舉措，推進腦機接口領域發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2659113553","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659113553?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 14:16","pubTimestamp":1786688167,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659713954","title":"美國研究綜述-愛彼迎、Five Below、Silgan Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2659713954","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659713954?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 14:50","pubTimestamp":1786603808,"startTime":"0","endTime":"0","summary":"美国研究综述-爱彼迎、Five Below、Silgan Holdings路透8月13日-周四，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括爱彼迎、Five Below和Silgan Holdings。股票按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4S44A0GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSW","NURE","EAT","MNPR","FLY","PTCT","BOAT","INO","MNSH","KURA","OSCR","PAYX","UNCY","FLYT","ACM","COHR","SPHR","TRIP","OII","ABNB","RHP","HP","PARK","ARMK","LLII","OZEM","CYTK","FIVE","SRRK","IBRN","ELIS","LLY","OI","CSCO","Z","AMRZ","MTSI","TRAX","ANRO","DUOL","SLGN","ZG","LQDA","YELP","CURE","LOW","CAH","ALGM","MSGE","AMTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138517","title":"美銀證券：中國CXO行業受惠生物科技融資強勁 上調藥明康德等目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138517?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 12:41","pubTimestamp":1786596060,"startTime":"0","endTime":"0","summary":"模拟交易客户端美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元，药明康德A股目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-13/doc-inincxku3329313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBC","CXO","SMCO","02359","SURI","FHLC","IDNA","LFSC","WX","BMED","161027","MEDI","XBIX","603259","PSIL","APXH","PSCH","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658774359","title":"尹弘在贛江新區調研：全力以赴搶佔產業新賽道打造新的增長點 奮發有為創造一流業績展現新區發展水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2658774359","media":"南昌发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658774359?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 20:10","pubTimestamp":1786536600,"startTime":"0","endTime":"0","summary":"赣江新区积极布局产业新赛道，聚力发展脑机接口产业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-12/doc-ininamim3883494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197232","title":"尹弘在贛江新區調研：全力以赴搶佔產業新賽道打造新的增長點 奮發有為創造一流業績展現新區發展水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197232","media":"江西发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658197232?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 19:39","pubTimestamp":1786534740,"startTime":"0","endTime":"0","summary":"8月12日，省委书记尹弘深入赣江新区调研。他强调，要全面贯彻落实省委十五届十次全会精神，立足自身功能定位，锐意改革创新，勇于担当作为，加快推进新旧动能转换，全力以赴抢占产业新赛道，打造新的经济增长点，奋发有为创造一流业绩、展现新区发展水平，为全省发展大局作出更大贡献。赣江新区积极布局产业新赛道，聚力发展脑机接口产业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-12/doc-ininaezp4000449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658268809","title":"韓國政府：計劃在2035年前實現腦機接口產品的商業化。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658268809","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658268809?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 13:32","pubTimestamp":1786512740,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928799","title":"浙江省：到2027年腦機接口未來產業營收超過50億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928799","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658928799?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 11:31","pubTimestamp":1786505489,"startTime":"0","endTime":"0","summary":"金吾财讯 | 8月12日，浙江省人民政府办公厅印发关于推进脑机接口产学研联动的若干措施的通知。到2027年，企业主导的产学研联动机制有效运行，脑机接口核心软硬件自主创新能力大幅提升，研发5个以上代表性产品并率先实现验证应用，脑机接口未来产业营收超过50亿元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MmE5ZmExMjY0NjZiOTEwNWRjYzNhYzE1NWFlMjE2MzgxNTIxMjk2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmE5ZmExMjY0NjZiOTEwNWRjYzNhYzE1NWFlMjE2MzgxNTIxMjk2.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928896","title":"腦機接口板塊走高，創新醫療漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928896","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658928896?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 11:08","pubTimestamp":1786504085,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658892886","title":"浙江：鼓勵腦機接口企業自主合理定價 開通醫用耗材掛網「綠色通道」","url":"https://stock-news.laohu8.com/highlight/detail?id=2658892886","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658892886?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 11:07","pubTimestamp":1786504067,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658789940","title":"浙江：強化腦機接口企業全生命周期金融支持 推動腦機接口企業選擇合適上市方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2658789940","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658789940?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 10:57","pubTimestamp":1786503432,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928863","title":"人保財險簽發全國首單腦機接口手術意外險","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928863","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658928863?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 10:56","pubTimestamp":1786503412,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月12日，中国人民保险集团附属人保财险宣布，为浙江大学医学院附属第二医院承保全国首单侵入式脑机接口手术意外险，率先填补国内该领域风险保障空白，探索形成“科技创新+医疗应用+保险保障”协同发展的新模式，以保险专业能力服务国家未来产业战略布局。针对这一行业痛点，人保财险定制研发脑机接口手术意外险，保障范围完整覆盖术中操作意外、术后并发症、诊疗过失等专属风险场景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658294044","title":"人保財險簽發全國首單腦機接口手術意外險","url":"https://stock-news.laohu8.com/highlight/detail?id=2658294044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658294044?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 10:49","pubTimestamp":1786502952,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658817985","title":"賓利把神經科學塞進車裏！首款純電Torcal內飾公開：座艙根據情緒變氛圍","url":"https://stock-news.laohu8.com/highlight/detail?id=2658817985","media":"快科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658817985?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 12:02","pubTimestamp":1786334520,"startTime":"0","endTime":"0","summary":"快科技8月10日消息，近日，宾利首款纯电跨界车Torcal 内饰细节公开，搭载名为Curation Engine的座舱氛围系统，以“感官神经科学”为基础，联动灯光、声音、温度、空气质量和数字界面，提供四种情绪模式。宾利官方提到该车还配备22向座椅调节。Torcal预计最大功率597kW，充电7分钟可补充161公里续航。宾利将于9月23日公布更多信息。这是宾利品牌首款纯电动车，也是继欧陆GT、飞驰和添越之后的第四条产品线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vTPgVe5Rm7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657267858","title":"「蒸餾」你的大腦，腦機這門生意竟然價值上億","url":"https://stock-news.laohu8.com/highlight/detail?id=2657267858","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657267858?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 17:45","pubTimestamp":1786182300,"startTime":"0","endTime":"0","summary":"2026年上半年，国内脑机接口领域发生了47起融资事件，披露总额超过53亿元，占这个赛道历史融资总额的近六成，单半年规模已远超2025年全年。据李昕介绍，华超是国内少数将超声作为核心技术路线、同时自研读取和干预闭环的非侵入式脑机接口公司。对一家成立刚满一年的脑机接口公司来说，这不寻常。这个团队负责建立大脑模型、识别调控焦点、理解干预效果，同时从脑机接口获","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656192457&idx=1&sn=cec0f965929313585aeaafeb70e4ef6f&chksm=67515f678502d728015d2320143f80e74e03b9631bfd2ecb7f6c4b5c740d4724c87ab8e8587f&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["VTHR","AGIX","MNTL","AIPO","IBRN","CHAT","QTOC","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629774","title":"更正-Scholar Rock將諾和諾德的生產設施從肌肉無力藥物的上市申請中剔除","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629774","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629774?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 05:28","pubTimestamp":1786138136,"startTime":"0","endTime":"0","summary":"更正-Scholar Rock将诺和诺德的生产设施从肌肉无力药物的上市申请中剔除更正：标题和第一段中应为诺和诺德位于印第安纳州的工厂，而非卡塔伦特Sneha S K路透8月7日-Scholar Rock公司周五表示，将从其向美国食品药品监督管理局提交的罕见神经肌肉疾病药物审批申请中，移除诺和诺德位于印第安纳州的制造工厂。Scholar Rock表示，该药物的批准决定仍按计划于9月30日作出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL4T4441MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","SRRK","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181955205","title":"Scholar Rock 因FDA質控警告，將諾和諾德工廠從藥物申請中剔除","url":"https://stock-news.laohu8.com/highlight/detail?id=1181955205","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181955205?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:51","pubTimestamp":1786135897,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding 正从其用于治疗脊髓性肌萎缩症的 apitegromab 生物制剂许可申请中，移除一座由诺和诺德拥有的灌装-封装设施。此举背景是，该设施因可能面临美国食品药品监督管理局的执法行动而被标记。Scholar Rock 透露，公司于周五收到客户通知，称FDA已将首个灌装-封装设施——即诺和诺德旗下的Catalent Indiana——在4月的一次现场检查后，归类为“官方行动指示”。“Scholar Rock 将继续与FDA密切合作，并遵循其指导，将Catalent Indiana从apitegromab的BLA中移除，”公司表示。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","NVO","PPH","NVOH","BK4139","LU0154236417.USD","BK4585","BK4007","LU1093756168.USD","BK4599","THNR","OZEM","SRRK","IBRN","IE00BZ1G4Q59.USD","NVOX","BK4532","BK4588","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109042786","title":"Scholar Rock Holding Corporation 已全面就緒，只待FDA批准即刻啓動Apitegromab美國上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1109042786","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109042786?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:21","pubTimestamp":1786134077,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corporation 已做好充分准备。一旦获得美国食品药品监督管理局（FDA）的批准，他们将立即启动Apitegromab在美国市场的上市。该公司正蓄势待发，静候监管绿灯的亮起，以便迅速将这款药物推向市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","THNR","IBRN","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180768754","title":"Scholar Rock宣佈FDA受理Apitegromab治療脊髓性肌萎縮症（SMA）的生物製品許可申請（BLA），並推進第二家灌裝-封裝工廠建設；預計2026年9月30日前作出審批決定","url":"https://stock-news.laohu8.com/highlight/detail?id=1180768754","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180768754?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:21","pubTimestamp":1786134073,"startTime":"0","endTime":"0","summary":"Scholar Rock公司今日宣布，美国食品药品监督管理局（FDA）已正式受理其针对Apitegromab用于治疗脊髓性肌萎缩症（SMA）的生物制品许可申请（BLA）。与此同时，该公司正积极推进第二家灌装-封装工厂的建设。市场预期，FDA将在2026年9月30日的行动日期前作出最终审批决定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","SRRK","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119566389","title":"Scholar Rock Holding Corp 與歐洲藥品管理局溝通，計劃將第二家灌裝-封裝設施納入Apitegromab上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1119566389","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119566389?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:21","pubTimestamp":1786134070,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corp 正积极与欧洲药品管理局（EMA）展开沟通。该公司旨在将第二处灌装-封装生产设施，纳入其实验性药物Apitegromab的上市许可申请（MAA）中。这一举措，凸显了其对于扩大生产能力的战略布局。通过此举，公司期望能优化供应链韧性，并确保未来药物获批后的稳定供应。此举不仅关乎生产规模，更体现了对监管流程的深度参与与前瞻性规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","BK4139","THNR","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657612550","title":"「蒸餾」你的大腦，腦機這門生意竟然價值上億","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612550","media":"虎嗅网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657612550?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 15:22","pubTimestamp":1786087345,"startTime":"0","endTime":"0","summary":"2026年上半年，国内脑机接口领域发生了47起融资事件，披露总额超过53亿元，占这个赛道历史融资总额的近六成，单半年规模已远超2025年全年。据李昕介绍，华超是国内少数将超声作为核心技术路线、同时自研读取和干预闭环的非侵入式脑机接口公司。对一家成立刚满一年的脑机接口公司来说，这不寻常。这个团队负责建立大脑模型、识别调控焦点、理解干预效果，同时从脑机接口获取新的模式反哺模型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vONreNLVH1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["QTOC","VTHR","IBRN","AIPO","MNTL","CHAT","ARTY","AGIX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}